Category: Workers Comp

523 posts found

IQVIA Reports on Global Oncology Trends

Global spending on cancer therapies now exceeds $133 billion.

Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.

A newly released draft guidance encourages the development of more sustained-release buprenorphine products.

In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.

Senate Bill 336 passed with a 44-6 vote and is now headed to the House.

Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.

In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.

If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.

Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.

A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.

A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.

Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.

Healthesystems’ Chief Medical Officer will present "Can Workers’ Comp Catch Up to the Rest of Healthcare?" at the 2018 IRSG Annual Conference.

Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.

Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management

Prev 1 2 3 4 5 … 31 32 33 34 35 Next